US-based biopharmaceutical services company Quintiles has launched web-based technology to support centralised patient outreach campaigns for clinical trial enrolment.

Branded as Quintiles Trial Enrollment Accelerator (QTEA), the new technology is designed to speed up patient recruitment by helping customers better manage the quality, consistency and effectiveness of their messaging.

It includes a full range of standardised templates, facilitating the creation of consistent, branded recruitment materials for all trial sites, Quintiles says. It allows clients to capitalise on existing local media intelligence and improved negotiating power, with the potential to reduce media costs by up to 50%.

QTEA also gives access to Quintiles’ proprietary opt-in patient database and referral network, driving “highly efficient one-to-one marketing”, the company adds. In addition, Quintiles will provide consultation on building a study-specific campaign, with communication elements designed for that particular protocol.

QTEA integrates with QRecruit, a web-based patient screening tool, and is part of Quintiles’ “holistic” patient recruitment solution, the company notes.

“On-time patient recruitment is the biggest challenge in clinical research today,” comments Chris Cabell, senior vice president, Access to Patients. “Direct outreach has become a vital component of on-time patient recruitment, with consistent evidence of breakthrough effectiveness. However, some biopharma companies are still reluctant to invest up-front in fully integrated, high quality communication plans for their studies.”

The result is that responsibility for creating and placing materials is typically left to individual sites, “giving rise to inconsistency, poor returns on investment and little to no visibility of programme effectiveness”, Cabell adds.